The story of the world's first human clinical trial of embryonic stem cell therapy and its unexpected conclusion
In January 2009, a milestone in medical history was reached when the biotechnology company Geron Corporation received U.S. Food and Drug Administration (FDA) clearance to begin the world's first human clinical trial of a therapy derived from human embryonic stem cells (hESCs). The groundbreaking trial aimed to treat patients with acute spinal cord injuries using GRNOPC1, a therapy containing hESC-derived oligodendrocyte progenitor cells.
At the time, Geron's CEO, Thomas Okarma, hailed it as "potentially a new chapter in medical therapeutics—one that reaches beyond pills to a new level of healing: the restoration of organ and tissue function".
Yet, merely two years later, in November 2011, Geron announced it was halting the landmark trial and exiting the stem cell business entirely1 . This decision sent shockwaves through the scientific community and raised fundamental questions about the future of embryonic stem cell research.
Embryonic stem cells are unique biological entities capable of turning into virtually any type of tissue in the human body1 . These pluripotent cells, first derived from human embryos in 19982 , can divide indefinitely while maintaining their capacity to differentiate into any cell type when provided with appropriate stimuli2 .
This remarkable potential sparked hopes that they might one day be used to create replacement cells or tissues to combat a vast array of degenerative diseases1 .
Geron's pioneering therapy, GRNOPC1, contained oligodendrocyte progenitor cells derived from human embryonic stem cells3 . Oligodendrocytes are crucial nervous system cells that produce myelin, the insulating material that surrounds nerve fibers and enables efficient electrical signaling in the nervous system.
In spinal cord injury, nerve fiber damage is often compounded by the loss of this protective myelin sheath.
Repair damaged nerve fibers by restoring the protective myelin sheath
Promote regeneration of damaged neural pathways
Improve locomotor activity and sensory function
Preclinical studies in animal models had shown promising results, with treated animals demonstrating significant improvement in locomotor activity when injected seven days after injury. Histological examinations revealed improved axon survival and extensive remyelination surrounding injured nerves.
Geron's Phase I clinical trial, initiated in October 20103 , was designed primarily to assess the safety and tolerability of GRNOPC1 in patients with complete thoracic spinal cord injuries3 . The study employed a carefully structured protocol:
Producing clinical-grade stem cell therapies required overcoming significant technical challenges:
| Aspect | Details |
|---|---|
| Cell Line Source | GRNOPC1 was derived from the H1 human embryonic stem cell line, which had been created before August 9, 2001, making it eligible for U.S. federal research funding |
| Manufacturing Standards | The cells were produced using current Good Manufacturing Practices (cGMP) in Geron's specialized facilities |
| Quality Assurance | Each batch underwent rigorous quality control testing for viability, sterility, and cellular composition before release for clinical use |
In November 2011, Geron announced it was halting the stem cell program and leaving the field entirely1 . The company cited financial considerations as the primary reason, explaining that with money scarce, it needed to focus its resources on cancer therapies that were further along in development1 .
CEO John Scarlett, who had taken the position less than two months earlier, emphasized that the decision "did not reflect a lack of promise for the controversial field"1 .
Geron's exit was widely perceived as a significant setback for embryonic stem cell research, given the company's central role in pioneering the field1 . The company had helped fund the initial derivation of human embryonic stem cells at the University of Wisconsin in the late 1990s, giving it fundamental patent rights in the field1 .
"This company would not walk away from this trial in the absence of an unexpected complication or safety concern, if there was any evidence that it was working"
"Very unfortunate for the field... puts the pressure on us now... everyone knew it was going to be very difficult to show efficacy"
| Reagent Type | Function | Importance for Clinical Translation |
|---|---|---|
| Specialized Culture Media | Provides nutrients and signaling molecules for cell growth | Must be serum-free or xeno-free to avoid immune reactions and contamination risks4 |
| Extracellular Matrices | Mimics the natural cellular environment for proper tissue development | Enables 3-D culture models; critical for proper cell differentiation9 |
| Cell Dissociation Reagents | Gently detaches adherent cells for passaging or administration | Animal origin-free versions (like recombinant trypsin alternatives) minimize viral contamination risk4 |
| Growth Factors & Cytokines | Directs stem cell differentiation into specific cell types | High lot-to-lot consistency ensures reproducible differentiation9 |
| Small Molecules | Controls stem cell maintenance, reprogramming, and differentiation | Defined mechanisms allow precise dosing and control of cell fate9 |
While Geron's exit from the field represented a significant setback, it also provided valuable lessons for the regenerative medicine community:
Geron's extensive work, including a 21,000-page IND application7 , created a regulatory roadmap for future stem cell therapies.
The company developed scalable manufacturing processes that could produce clinical-grade cells in quantities sufficient for commercial applications.
The challenges highlighted the need to reconsider which diseases represent the most viable initial targets for stem cell therapies.
Growing interest in induced pluripotent stem cells (iPSCs) which circumvent ethical controversies and immune rejection concerns6 .
Fifteen years after Geron's historic trial began, the company has transformed into a commercial-stage biopharmaceutical company focused on cancer treatments, with its first drug, RYTELO, approved in 20248 . Meanwhile, embryonic stem cell research continues, though the pace of clinical translation has been slower than initially anticipated. The story of Geron's pioneering effort remains a testament to both the extraordinary challenges and enduring promise of regenerative medicine—a field still working to deliver on its potential to "change lives by changing the course" of degenerative diseases8 .